Protalix BioTherapeutics (PLX) Insider Trading & Ownership $1.66 +0.08 (+5.06%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.64 -0.02 (-1.51%) As of 08/22/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Protalix BioTherapeutics (NYSE:PLX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.50%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$206.40KNumber OfInsiders Selling(Last 12 Months)0 Get PLX Insider Trade Alerts Want to know when executives and insiders are buying or selling Protalix BioTherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address PLX Insider Buying and Selling by Quarter Protalix BioTherapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/10/2025Aharon SchwartzDirectorBuy129,000$1.60$206,400.00 (Data available from 1/1/2013 forward) PLX Insider Trading Activity - Frequently Asked Questions Who is on Protalix BioTherapeutics' Insider Roster? The list of insiders at Protalix BioTherapeutics includes Aharon Schwartz, and Dror Bashan. Learn more on insiders at PLX. What percentage of Protalix BioTherapeutics stock is owned by insiders? 6.50% of Protalix BioTherapeutics stock is owned by insiders. Learn more on PLX's insider holdings. Which Protalix BioTherapeutics insiders have been buying company stock? The following insiders have purchased PLX shares in the last 24 months: Aharon Schwartz ($206,400.00), and Dror Bashan ($90,322.40). How much insider buying is happening at Protalix BioTherapeutics? Insiders have purchased a total of 193,516 PLX shares in the last 24 months for a total of $296,722.40 bought. Protalix BioTherapeutics Key ExecutivesMr. Dror Bashan (Age 57)President, CEO & Director Compensation: $1.38MMr. Eyal Rubin M.B.A. (Age 48)Senior VP, CFO, Treasurer & Corporate Secretary Compensation: $686.78kMr. Yaron Naos (Age 60)Senior Vice President of Operations Compensation: $513.82kMs. Yael FellousVice President of Human Resources More Insider Trading Tools from MarketBeat Related Companies MBX Biosciences Insider Selling aTyr Pharma Insider Selling Solid Biosciences Insider Selling Prime Medicine Insider Selling Erasca Insider Selling Eton Pharmaceuticals Insider Selling Cullinan Therapeutics Insider Selling Tonix Pharmaceuticals Insider Selling iTeos Therapeutics Insider Selling Gossamer Bio Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say BuyStrategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying This page (NYSE:PLX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access